Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years
- Resource Type
- Short Communication
- Source
- In
The Journal of Allergy and Clinical Immunology: In Practice October 2020 8(9):3219-3221 - Subject
- Language
- ISSN
- 2213-2198